Airway Therapeutics announced expansion of its Phase III trial of zelpultide alfa, a recombinant surfactant protein D analog, in preterm neonates with bronchopulmonary dysplasia. The multinational trial now includes over 300 infants across 90 sites worldwide. This therapy aims to reduce lung inflammation and injury by modulating immune pathways and improving surfactant function, addressing a leading cause of morbidity in extremely premature infants.